Dalbavancin as consolidation antibiotic treatment in infective endocarditis, cardiac implantable electronic devices infection and bacteremia: Clinical experience of 7 years
Enfermedades infecciosas y microbiologia clinica (English ed.) · 2025
DOI: 10.1016/j.eimce.2024.05.009 ↗Kurz gefasst
Fachartikel in der Zeitschrift Enfermedades infecciosas y microbiologia clinica (English ed.), 2025. Verfasst von Alejandro Salinas-Botrán und 5 weiteren Autor:innen. Beteiligte Einrichtung: Servicio de Medicina Interna, Hospital Clínico San Carlos, Madrid, Spain; Universidad Complutense de Madrid, Madrid, Spain. Electronic address: asali…. Hauptthemen laut MEDLINE: Teicoplanin, Bacteremia, Anti-Bacterial Agents, Prosthesis-Related Infections. Die Arbeit nennt 37 Literaturangaben.
Abstract (Originalsprache)
INTRODUCTION: Dalbavancin (DBV), a novel lipoglycopeptide with activity against Gram-positive bacterial infections, is approved for the treatment of acute bacterial skin and skin structure infections (ABSSSIs). It has linear dose-related pharmacokinetics allowing a prolonged interval between doses. It would be a good option for the treatment of patients with Gram-positive cardiovascular infections. METHODS: Retrospective analysis of patients with cardiovascular infection (infective endocarditis, bacteremia, implantable electronic device infection) treated with DBV at Hospital Clínico San Carlos (Madrid) for 7 years (2016-2022). Patients were divided in two study groups: 1) Infective endocarditis (IE), 2) Bacteremia. Epidemiological, clinical, microbiological and therapeutic data were analyzed. RESULTS: A total of 25 patients were treated with DBV for cardiovascular infection. IE was the most common indication (68%), followed by bacteremia (32%) with male predominance in both groups (64% vs 62%) and median age of 67,7 and 57,5 years, respectively. 100% of blood cultures were positive to Gram-positive microorganisms (Staphylococcus spp., Streptococcus spp. or Enterococcus spp.) in both study groups. Previously to DBV, all patients received other antibiotic therapy, both in the group of IE (median: 80 days) as in bacteremia (14,8 days). The main reason for the administration of DBV was to continue intravenous antimicrobial therapy outside the hospital in both the EI group (n = 15) and the bacteremia group (n = 8). DBV was used as consolidation therapy in a once- or twice-weekly regimen. Microbiological and clinical successes were reached in 84% of cases (n = 21), 76,4% in IE group and 100% in bacteremia group. No patient documented adverse effects during long-term dalbavancin treatment. CONCLUSION: DBV is an effective and safety treatment as consolidation antibiotic therapy in IE and bacteremia produced by Gram-positive microorganisms.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Servicio de Medicina Interna, Hospital Clínico San Carlos, Madrid, Spain; Universidad Complutense de Madrid, Madrid, Spain. Electronic address: asalinasbotran@yahoo.es.
- Servicio de Cardiología, Hospital Clínico San Carlos, Madrid, Spain; Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdSSC), Madrid, Spain.
- Servicio de Medicina Hospitalaria, Hospital Clínico San Carlos, Madrid, Spain.
- Servicio de Medicina Interna, Hospital Clínico San Carlos, Madrid, Spain.
- Servicio de Nefrología, Hospital Clínico San Carlos, Madrid, Spain.
Zitieren
APA
Salinas-Botrán, A., Olmos-Blanco, C., Fernández de Velasco-Pérez, D., Guzmán-Carreras, A., Morales-Rosas, A., & Gómez-Ramírez, D. (2025). Dalbavancin as consolidation antibiotic treatment in infective endocarditis, cardiac implantable electronic devices infection and bacteremia: Clinical experience of 7 years. Enfermedades infecciosas y microbiologia clinica (English ed.). https://doi.org/10.1016/j.eimce.2024.05.009
Vancouver
Salinas-Botrán A, Olmos-Blanco C, Fernández de Velasco-Pérez D, Guzmán-Carreras A, Morales-Rosas A, Gómez-Ramírez D. Dalbavancin as consolidation antibiotic treatment in infective endocarditis, cardiac implantable electronic devices infection and bacteremia: Clinical experience of 7 years. Enfermedades infecciosas y microbiologia clinica (English ed.). 2025. doi:10.1016/j.eimce.2024.05.009
BibTeX
@article{SalinasBotrn2025,
author = {Salinas-Botrán, Alejandro and Olmos-Blanco, Carmen and Fernández de Velasco-Pérez, David and Guzmán-Carreras, Alicia and Morales-Rosas, Alejandro and Gómez-Ramírez, Daniel},
title = {Dalbavancin as consolidation antibiotic treatment in infective endocarditis, cardiac implantable electronic devices infection and bacteremia: Clinical experience of 7 years},
journal = {Enfermedades infecciosas y microbiologia clinica (English ed.)},
year = {2025},
doi = {10.1016/j.eimce.2024.05.009}
}
EUVIMED